Get the latest tech news
University spin-out Afynia secures $5M seed to commercialize its microRNA panel test for endometriosis
Canadian biotech startup Afynia Laboratories, a spin-out from McMaster University in Ontario, has picked up $5 million in seed funding to commercialize a
Canadian biotech startup Afynia Laboratories, a spin-out from McMaster University in Ontario, has picked up $5 million in seed funding to commercialize a blood test for endometriosis — a medical condition that can afflict people with a uterus, causing problems like chronic pelvic pain and fertility issues. While Afynia ( previously called AIMA) was founded back in November 2021, Foster says the EndomiR test technology draws on the long span of her research career focused on ovarian regulation and endometriosis — which, since around 2015, included looking at microRNA, too. Hence, along with her PhD student and now co-founder, Dr. Jocelyn Wessel (also pictured in the above feature image), they decided to take the IP they’d developed on microRNAs and form their own company with the goal of commercializing a non-invasive (in the sense of not requiring a surgical diagnosis) endometriosis test to market.
Or read this on TechCrunch
